{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:15:06Z","timestamp":1784837706227,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1302000"],"award-info":[{"award-number":["2021YFA1302000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011840","name":"Shantou University Medical College","doi-asserted-by":"publisher","award":["0001408"],"award-info":[{"award-number":["0001408"]}],"id":[{"id":"10.13039\/501100011840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172917"],"award-info":[{"award-number":["82172917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drup.2026.101432","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:45:08Z","timestamp":1780674308000},"page":"101432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance"],"prefix":"10.1016","volume":"88","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-7216","authenticated-orcid":false,"given":"Muhammad","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-2001","authenticated-orcid":false,"given":"Hong-Jian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-2627","authenticated-orcid":false,"given":"Hanwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulloev","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0629-7661","authenticated-orcid":false,"given":"Xinya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101432_bib1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101432_bib2","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1158\/1078-0432.CCR-16-2174","article-title":"Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance","volume":"23","author":"Afghahi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101432_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101432_bib4","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1242\/jcs.039115","article-title":"Radiation-induced mitotic catastrophe in PARG-deficient cells","volume":"122","author":"Ame","year":"2009","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.drup.2026.101432_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2026.101432_bib6","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101432_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101432_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2012.06.016","article-title":"The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease","volume":"16","author":"Bai","year":"2012","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101432_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101432_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202003598","article-title":"Neutrophils Enable Local and Non-Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart","volume":"32","author":"Che","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2026.101432_bib15","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/onc.2011.395","article-title":"Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma","volume":"31","author":"Chen","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101432_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.celrep.2014.08.076","article-title":"BRCA1 accelerates CtIP-mediated DNA-end resection","volume":"9","author":"Cruz-Garcia","year":"2014","journal-title":"Cell. Rep."},{"key":"10.1016\/j.drup.2026.101432_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101432_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12885-021-09145-0","article-title":"Late effects of high-dose methotrexate treatment in childhood cancer survivors-a systematic review","volume":"22","author":"Daetwyler","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101432_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101432_bib20","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.2147\/CMAR.S274913","article-title":"PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma","volume":"12","author":"Deng","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.drup.2026.101432_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ccell.2021.04.016","article-title":"The loss of RNA N(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth","volume":"39","author":"Dong","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101432_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217309","article-title":"Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies","volume":"607","author":"Dong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101432_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.drup.2026.101432_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/phrs.1996.0126","article-title":"L-histidine\/medroxyprogesterone acetate interaction modulates human breast cancer cell growth and progestin receptor expression in vitro","volume":"35","author":"Ghezzo","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drup.2026.101432_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101432_bib30","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1128\/AEM.71.4.1883-1889.2005","article-title":"Folate cross-feeding supports symbiotic homoacetogenic spirochetes","volume":"71","author":"Graber","year":"2005","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.drup.2026.101432_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.devcel.2016.02.012","article-title":"Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells","volume":"36","author":"Hosios","year":"2016","journal-title":"Dev. Cell."},{"key":"10.1016\/j.drup.2026.101432_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.drup.2026.101432_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.it.2012.11.001","article-title":"Epigenetic regulation of macrophage polarization and function","volume":"34","author":"Ivashkiv","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2026.101432_bib34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/0008-5472.CAN-14-0839","article-title":"BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance","volume":"75","author":"Jaspers","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101432_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell. Res."},{"key":"10.1016\/j.drup.2026.101432_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41586-018-0316-7","article-title":"Histidine catabolism is a major determinant of methotrexate sensitivity","volume":"559","author":"Kanarek","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-020-2124-0","article-title":"Dietary modifications for enhanced cancer therapy","volume":"579","author":"Kanarek","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bju.15276","article-title":"Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"127","author":"Kardoust Parizi","year":"2021","journal-title":"BJU Int."},{"key":"10.1016\/j.drup.2026.101432_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101432_bib40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib41","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.15252\/emmm.201404824","article-title":"Folate levels modulate oncogene-induced replication stress and tumorigenicity","volume":"7","author":"Lamm","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.drup.2026.101432_bib42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1387\/ijdb.113371dl","article-title":"Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions","volume":"55","author":"Laoui","year":"2011","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.drup.2026.101432_bib43","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101432_bib44","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib45","article-title":"With great power comes great vulnerability","volume":"5","author":"Leite de Oliveira","year":"2018","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0738-081X(89)90014-X","article-title":"Methotrexate","volume":"7","author":"Lester","year":"1989","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.drup.2026.101432_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2016.11.003","article-title":"Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-\u03baB\/IL-6 signals","volume":"386","author":"Liang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101432_bib48","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/gutjnl-2018-316324","article-title":"Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer","volume":"68","author":"Lin","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.drup.2026.101432_bib49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101432_bib50","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101432_bib51","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.drudis.2016.12.003","article-title":"Targeting amino acid metabolism for cancer therapy","volume":"22","author":"Lukey","year":"2017","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.drup.2026.101432_bib52","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S40947","article-title":"Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review","volume":"7","author":"Marchetti","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101432_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib55","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.trecan.2023.06.003","article-title":"Diet, nutrient supply, and tumor immune responses","volume":"9","author":"McIntyre","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101432_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101432_bib57","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3389\/fimmu.2018.02858","article-title":"Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase","volume":"9","author":"Namgaladze","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101432_bib58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101432_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.dnarep.2015.04.008","article-title":"The rise and fall of poly(ADP-ribose): An enzymatic perspective","volume":"32","author":"Pascal","year":"2015","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.drup.2026.101432_bib60","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1038\/onc.2008.35","article-title":"Immune escape as a fundamental trait of cancer: focus on IDO","volume":"27","author":"Prendergast","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101432_bib61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib62","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201302145","article-title":"The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression","volume":"201","author":"Reczek","year":"2013","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.drup.2026.101432_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101432_bib64","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101432_bib65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101432_bib66","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101432_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","article-title":"The folate receptor: what does it promise in tissue-targeted therapeutics?","volume":"26","author":"Salazar","year":"2007","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.drup.2026.101432_bib68","first-page":"728","article-title":"Programmed cell death protein-1\/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role","volume":"4","author":"Santarpia","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.drup.2026.101432_bib69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101432_bib70","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1158\/0008-5472.CAN-11-0375","article-title":"Roles of sildenafil in enhancing drug sensitivity in cancer","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101432_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2026.101432_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.drup.2026.101432_bib73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1230624","article-title":"Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching","volume":"339","author":"Virgilio","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101432_bib74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101432_bib75","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell. Metab."},{"key":"10.1016\/j.drup.2026.101432_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","article-title":"Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy","volume":"16","author":"Yang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101432_bib77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-022-01512-0","article-title":"PBK\/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study","volume":"21","author":"Yang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101432_bib78","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","article-title":"Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","volume":"72","author":"Ying","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101432_bib79","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:48:10Z","timestamp":1784836090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876462600083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"alternative-id":["S136876462600083X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101432","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101432"}}